Jacob Funds Invests in Prime Medicine, A Gene Therapy Company with Potential for Broader Adoption

Jacob Funds highlights Prime Medicine (PRME) as a next-generation gene therapy company with significant upside potential. The fund believes in Prime Medicine's technology and its potential to cure chronic and deadly diseases. The company's gene editing function is precise and safer than traditional gene therapy technologies. The fund adds that Prime Medicine's recent clinical trial showed promising efficacy and safety signals.